{"created":"2023-07-25T10:23:32.537046+00:00","id":3227,"links":{},"metadata":{"_buckets":{"deposit":"7d3c0a98-5acb-4d6c-9ffa-b7d18afc6e71"},"_deposit":{"created_by":15,"id":"3227","owners":[15],"pid":{"revision_id":0,"type":"depid","value":"3227"},"status":"published"},"_oai":{"id":"oai:air.repo.nii.ac.jp:00003227","sets":["611:862:863:1161"]},"author_link":["9499","9468","6135","10230","10231","10232","11070","10234","11071","10235","10236","10237","10238","10239","11072","11073","10221"],"item_10001_biblio_info_7":{"attribute_name":"bibliographic_information","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2018-03","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"3/4","bibliographicPageEnd":"109","bibliographicPageStart":"101","bibliographicVolumeNumber":"44","bibliographic_titles":[{"bibliographic_title":"秋田医学","bibliographic_titleLang":"ja"},{"bibliographic_title":"Akita journal of medicine","bibliographic_titleLang":"en"}]}]},"item_10001_description_5":{"attribute_name":"内容記述","attribute_value_mlt":[{"subitem_description":"AIM : To assesse the efficacy and safety of therapy with daclatasvir (DCV) and asunaprevir (ASV) for HCV genotype 1. METHOD : The study population was 253 patients who were enrolled in the Akita hepatitis C study group from 2015 to 2016. We followed them until 24 weeks after the end of treatment. RESULT : The sustained virological response (SVR) at 24 weeks after the end of treatment rates were 84.2%. In univariate analyses, the Y93 mutation and a history of triple therapy with protease inhibitor reduced the SVR 24 rate. In multivariate analyses, the Y93H mutation, a history of triple therapy with protease inhibitor, and LC status reduced the SVR 24 rate. The most frequently reported adverse event was ALT elevation, noted in 25.7% of patients. 10.7% of patients had T-Bil elevation, 7.1% experienced drug rush, 11.5% experienced respiratory symptoms, 10.3% developed a fever, and 7.1% experienced digestive symptom. Only 9 (3.6%) patients stopped taking the drugs due to drug-related severe adverse events. CONCLUSION : DCV and ASV therapy showed a high efficacy and low rate of adverse events.","subitem_description_language":"en","subitem_description_type":"Abstract"}]},"item_10001_identifier_registration":{"attribute_name":"identifier_registration","attribute_value_mlt":[{"subitem_identifier_reg_text":"10.20569/00003587","subitem_identifier_reg_type":"JaLC"}]},"item_10001_publisher_8":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"秋田医学会","subitem_publisher_language":"ja"}]},"item_10001_version_type_20":{"attribute_name":"出版タイプ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_1724099666130":{"attribute_name":"収録物識別子","attribute_value_mlt":[{"subitem_source_identifier":"0386-6106","subitem_source_identifier_type":"PISSN"},{"subitem_source_identifier":"AN00009294","subitem_source_identifier_type":"NCID"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"open access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_abf2"}]},"item_creator":{"attribute_name":"作成者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"AJIMINE, Takuma","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"9499","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"OHSHIMA, Shigetoshi","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"9468","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"GOTO, Takashi","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"6135","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"KOMATSU, Masafumi","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"10230","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"NAKANE, Kunio","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"10231","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"YAGISAWA, Hitoshi","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"10232","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Goto, Mitsuo","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"11070","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"NAKAJIMA, Kou","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"10234","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Miura, Masato","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"11071","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"FUNAOKA, Masato","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"10235","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"HOSHINO, Takao","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"10236","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"KURAMITSU, Tomoyuki","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"10237","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"FUJISHIMA, Yuukou","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"10238","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"WATANABE, Daisuke","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"10239","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Segawa, Daisuke","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"11072","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Inomata, Masaaki","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"11073","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"IIJIMA, Katsunori","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"10221","nameIdentifierScheme":"WEKO"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2018-07-05"}],"displaytype":"detail","filename":"akitai44_3_4(101).pdf","filesize":[{"value":"787.9 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"akitai44_3_4(101)","url":"https://air.repo.nii.ac.jp/record/3227/files/akitai44_3_4(101).pdf"},"version_id":"8152508c-aee3-4648-b824-1e91e8d90e43"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"hepatitis C virus","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"interferon free","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"daclatasvir","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"asunaprevir","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"α fetoprotein","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"item_resource_type","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"EFFICACY AND SAFETY OF TREATMENT WITH DACLATASVIR AND ASUNAPREVIR FOR HEPATITIS C VIRUS GENOTYPE 1","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"EFFICACY AND SAFETY OF TREATMENT WITH DACLATASVIR AND ASUNAPREVIR FOR HEPATITIS C VIRUS GENOTYPE 1","subitem_title_language":"en"}]},"item_type_id":"10001","owner":"15","path":["1161"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2018-07-05"},"publish_date":"2018-07-05","publish_status":"0","recid":"3227","relation_version_is_last":true,"title":["EFFICACY AND SAFETY OF TREATMENT WITH DACLATASVIR AND ASUNAPREVIR FOR HEPATITIS C VIRUS GENOTYPE 1"],"weko_creator_id":"15","weko_shared_id":-1},"updated":"2024-09-20T02:56:33.389160+00:00"}